Rep. Julia Letlow Buys Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares

Representative Julia Letlow (Republican-Louisiana) recently bought shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). In a filing disclosed on March 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on February 12th. The trade occurred in the Representative’s “MERRILL LYNCH INVESTMENT ACCOUNT #025” account.

Representative Julia Letlow also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of HF Sinclair (NYSE:DINO) on 2/20/2026.
• Sold $1,001 – $15,000 in shares of BXP (NYSE:BXP) on 2/20/2026.
• Purchased $1,001 – $15,000 in shares of Travelers Companies (NYSE:TRV) on 2/20/2026.
• Sold $1,001 – $15,000 in shares of Expand Energy (NASDAQ:EXE) on 2/17/2026.
• Sold $1,001 – $15,000 in shares of Public Service Enterprise Group (NYSE:PEG) on 2/17/2026.
• Purchased $1,001 – $15,000 in shares of Vistra (NYSE:VST) on 2/17/2026.
• Sold $1,001 – $15,000 in shares of Icon (NASDAQ:ICLR) on 2/12/2026.
• Purchased $1,001 – $15,000 in shares of Extra Space Storage (NYSE:EXR) on 2/12/2026.
• Sold $1,001 – $15,000 in shares of AT&T (NYSE:T) on 2/12/2026.
• Sold $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 2/12/2026.

Regeneron Pharmaceuticals Trading Up 1.0%

Shares of NASDAQ REGN traded up $7.11 during midday trading on Wednesday, hitting $748.80. The stock had a trading volume of 241,945 shares, compared to its average volume of 762,004. The firm has a market cap of $79.16 billion, a P/E ratio of 18.03, a price-to-earnings-growth ratio of 1.98 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The company’s 50-day simple moving average is $764.37 and its 200 day simple moving average is $704.03.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $12.07 earnings per share. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were paid a $0.94 dividend. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,274 shares of company stock valued at $4,142,738 in the last ninety days. Corporate insiders own 7.02% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. WPG Advisers LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares during the period. SHP Wealth Management acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth $26,000. Salomon & Ludwin LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth about $27,000. Titan Wealth CI Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $29,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $31,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Japan approval — Japan authorized Dupixent (dupilumab) as the first targeted therapy for adult bullous pemphigoid (BP), based on a pivotal trial showing >4x sustained remission vs. placebo; this adds a seventh Dupixent indication in Japan and should support incremental Dupixent sales in an underserved indication. Dupixent approved in Japan for bullous pemphigoid
• Positive Sentiment: Analyst/market momentum — A Zacks piece highlights REGN’s ~28.9% six‑month rally and suggests further upside potential in 2026 as pipeline wins and Dupixent growth help offset Eylea revenue erosion from intensifying retinal competition. That positive narrative likely supports investor appetite. REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
• Neutral Sentiment: Short-interest notices appear unreliable — multiple short‑interest reports flagged a “large increase” but show zero shares / NaN increases and a days‑to‑cover of 0.0; this looks like data noise rather than a meaningful build in short pressure. (Report entries from March 24.)
• Negative Sentiment: Competitive risk — Apogee Therapeutics reported Phase 2 eczema data suggesting longer‑lasting dosing could challenge Dupixent’s atopic dermatitis franchise; Apogee shares jumped ~20% on the readout, indicating potential long‑term pressure on Dupixent market share if later‑stage data confirm the benefit. Apogee strengthens case for longer-lasting eczema drug

Analysts Set New Price Targets

REGN has been the topic of a number of research reports. Evercore upped their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research report on Thursday, January 22nd. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their price target for the stock from $627.00 to $860.00 in a research report on Wednesday, January 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Oppenheimer restated an “outperform” rating and set a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Finally, Wall Street Zen cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $802.27.

About Representative Letlow

Julia Letlow (Republican Party) is a member of the U.S. House, representing Louisiana’s 5th Congressional District. She assumed office on April 14, 2021. Her current term ends on January 3, 2027.

Letlow (Republican Party) is running for re-election to the U.S. House to represent Louisiana’s 5th Congressional District. She declared candidacy for the primary scheduled on November 3, 2026.

Julia Letlow earned a doctorate. Letlow’s career experience includes working as a senior administrator with the University of Louisiana at Monroe.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.